Actively Recruiting

Age: 0Years - 100Years
All Genders
NCT03327428

Sickle-cell Disease Registry of the GPOH

Led by University Hospital Heidelberg · Updated on 2025-01-24

1000

Participants Needed

1

Research Sites

1254 weeks

Total Duration

On this page

Sponsors

U

University Hospital Heidelberg

Lead Sponsor

G

GPOH Consortium Sickle Cell Disease

Collaborating Sponsor

AI-Summary

What this Trial Is About

Sickle cell disease is one of the most common hereditary diseases. Most severe complications can be avoided if the disease is detected early and treated appropriately. The sickle cell disease registry of the Society for Paediatric Oncology/Haematology aims at describing the epidemiology of sickle cell disease in German-speaking central Europe. Patients with sickle cell disease will be characterized clinically and genetically and treatment will be documented with the aim to find predictors of the course of disease. In addition, the registry results should provide a solid evidence base to incorporate sickle cell disease into routine newborn screening and to update the national guidelines for the management of patients suffering from sickle cell disease in Germany. A consortium of five university hospitals (Berlin, Frankfurt, Hamburg, Heidelberg, Ulm) has been mandated by the Society for Paediatric Oncology/Haematology to implement this registry. The number of participating centers is constantly increasing and new centers that take care of either pediatric or adult patients with sickle cell disease are encouraged to support the registry. For further information please refer to: http://www.sichelzellkrankheit.info/

CONDITIONS

Official Title

Sickle-cell Disease Registry of the GPOH

Who Can Participate

Age: 0Years - 100Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed informed consent
  • Current residency in either Germany, Austria, or Switzerland
  • Confirmed diagnosis of sickle cell disease by hemoglobin or molecular genetic analysis, including:
    • Homozygous sickle cell disease (HbSS)
    • HbSC disease
    • Sickle cell disease HbS / beta-Thalassemia
    • Other rare sickle cell syndromes such as HbS/OArab, HbS/HPFH, HbS/E, HbS/D Punjab, HbS/C Harlem, HbC/S Antilles, HbS/Quebec-CHORI, HbA/S Oman, HbA/Jamaica Plain
Not Eligible

You will not qualify if you...

  • Isolated heterozygous trait for HbS (sickle cell carrier without disease)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Center for Child and Adolescent Medicine, University Medical Center Heidelberg

Heidelberg, Baden-Wurttemberg, Germany, 69124

Actively Recruiting

Loading map...

Research Team

J

Joachim Kunz, Dr.

CONTACT

L

Laura Tagliaferri, Dr.

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Sickle-cell Disease Registry of the GPOH | DecenTrialz